Privia Health Insiders Sell $11M as Analysts Remain Bullish

Forward-Looking Analysis

Wall Street analysts currently hold a consensus "Moderate Buy" rating for Privia Health Group, Inc., with an average target price of $31.15, indicating potential upside from current trading levels near the $23.67 open. The analyst community comprises eleven Buy ratings, two Holds, and one Sell rating. Specific recent actions include Citigroup reissuing a "Buy" rating on July 23, 2026, while Zacks Research downgraded the stock to a "Strong Sell" on July 7, 2026. Evercore set a price target of $26.00 on April 8, 2026, and Barclays reduced its objective from $25.00 to $24.00 on May 26, 2026, maintaining an "Equal Weight" rating. Weiss Ratings upgraded its rating from "Hold (C-)" to "Hold (C)" on July 2, 2026. Institutional ownership remains high at 94.48%, with significant activity from major holders. Dimensional Fund Advisors increased its stake by 6.3% in Q1 2026, holding 1.92% of the company. Conversely, First Trust Advisors LP reduced its position by 25.1% in Q1 2026. Renaissance Group LLC initiated a new position valued at approximately $7,776,000 in Q4 2025. Principal Financial Group Inc. raised its holdings by 1.6% in Q4 2025. Van Berkom & Associates Inc. increased its position by 5.4% in Q1 2026. The stock currently trades with a price-to-earnings ratio of 147.95 and a PEG ratio of 1.87.

Historical Performance Review

Privia Health reported Q1 2026 revenue of $603.85 million, with a gross profit of $535.43 million. Net income stood at $3.71 million, resulting in an EPS of $0.02. These figures reflect the company's operational scale and margin structure as it prepares for the upcoming Q2 release.

Additional News

Recent insider trading activity shows significant selling by executives. CEO Parth Mehrotra sold 15,647 shares on May 12, 2026, at an average price of $22.64, for a total value of $354,248.08, reducing his ownership by 3.48%. Director Matthew Shawn Morris sold 53,722 shares on July 6, 2026, at $27.24 per share, totaling $1,463,387.28, a 44.07% decrease in his position. CFO David Mountcastle sold 21,275 shares on July 9, 2026, at $27.67 per share, totaling $588,679.25, reducing his stake by 11.43%. All transactions were executed under pre-arranged Rule 10b5-1 trading plans to cover tax withholding obligations related to equity vesting. In the last ninety days, insiders collectively sold 452,357 shares worth $11,436,655. Corporate insiders currently own 5.70% of the stock. Institutional investors continue to adjust positions, with Dimensional Fund Advisors increasing holdings by 6.3% in Q1 2026. Other institutional movements include Hantz Financial Services Inc. boosting its stake by 456.2% in Q4 2025 and Global Retirement Partners LLC growing its position by 579.8% in Q4 2025. Canada Pension Plan Investment Board increased its stake by 48.0% in Q2 2025. Despite insider selling, institutional ownership remains robust at 94.48%.

Summary & Outlook

Privia Health demonstrates solid top-line growth with $603.85 million in Q1 revenue, though net margins remain thin at $3.71 million. The company faces headwinds from high valuation multiples (P/E of 147.95) and recent insider selling by key executives, signaling potential caution. However, the "Moderate Buy" analyst consensus and $31.15 average target price suggest underlying confidence in the physician enablement model. Institutional accumulation by entities like Dimensional Fund Advisors supports long-term viability. While insider activity raises short-term sentiment risks, the strategic positioning in value-based care provides a foundation for growth. The outlook remains cautiously optimistic, dependent on Q2 margin expansion and sustained institutional support.